STUDIES

Highlights Multi-center, randomized, double-blind, placebo-controlled trial Participants include 460 patients with diabetes and mild-to-moderate polyneuropathy Supplementation consists of ALA (600 mg/day) for 4 years ALA has no effect on a...

Highlights Assessment includes 5 randomized, double-blind, placebo-controlled trials with 1,160 subjects Alpha lipoic acid shown to provide symptomatic relief of diabetic polyneuropathy Effect oral dosage is 600 mg/day for up...

Highlights Meta-analysis of 24 randomized, controlled trials with patients with metabolic diseases ALA supplementation ranges from 200 to 1,800 mg/day Study duration ranges from 2 to 51 weeks ALA supplementation significantly improves glycemic...

Highlights Post-hoc analysis of the NATHAN 1 trial Participants include 460 patients with diabetes and mild-to-moderate polyneuropathy Supplementation consists of ALA (600 mg/day) for 4 years ALA treatment is particularly...

Highlights Randomized, double-blind, cross-over, placebo-controlled study Participants include healthy (n=19) and functionally constipated (n=9) adults Low-dose Actazin™ (600 mg/day) for 28 days significantly increases bowel movements in healthy “responders” without...